CoreWeave, Core Scientific Shares Slide on $9B Acquisition Deal

CoreWeave (CRWV) has announced an all-stock acquisition of its data center partner Core Scientific (CORZ) for approximately $9 billion, aiming to integrate Core Scientific's data center operations to "future-proof" its revenue growth in the high-performance computing sector. Following the announcement, CoreWeave's shares experienced a modest 2% decline, while Core Scientific's stock fell 13%, although it remains up 25% since initial deal speculation. This strategic move, expected to close in Q4 2025, deepens CoreWeave's capacity in providing Nvidia GPU access for AI computing, leveraging its existing partnership with Core Scientific.

Analysis

CoreWeave (CRWV) is executing a strategic vertical integration by acquiring its partner Core Scientific (CORZ) in a $9 billion all-stock transaction. The deal aims to secure essential data center infrastructure to support CoreWeave's primary business of renting high-demand Nvidia GPU capacity for AI applications. The market's reaction was mixed, with CoreWeave's shares declining 2%, a common response for an acquirer in an all-stock deal due to dilution, while Core Scientific's shares fell 13% to approximately $16 in a 'sell the news' event. However, the announced deal price of $20.40 per share represents a significant premium to the current trading price and is substantially higher than a $5.75 per share offer rejected last year, reflecting the rapidly increasing valuation of AI-related infrastructure. Despite the daily drop, Core Scientific's stock remains up 25% since M&A speculation began, indicating much of the premium was already priced in. With an expected close in Q4 2025, this long-term move highlights how high-flying AI companies like CoreWeave, which has seen its stock quadruple since March, are leveraging their equity to secure their supply chain and 'future-proof' growth.

Key Decisions for Investors

• CoreWeave investors should view this as a long-term strategic move to de-risk its infrastructure supply chain, but must factor in the dilutive effect of the all-stock offer and the execution risk associated with a large integration expected to close in late 2025.
• For Core Scientific shareholders, the $20.40 offer price presents a significant arbitrage opportunity over the current ~$16 price, though this is contingent on the deal closing successfully, creating a long-dated M&A arbitrage play with associated regulatory and timeline risks.
• The transaction underscores the intense competition for data center assets, signaling potential for further consolidation in the AI infrastructure space; investors should monitor other data center operators and hardware providers as potential M&A targets.